Bleomycin Sulfate

製品コードS1214 別名:NSC125066

Bleomycin Sulfate化学構造

分子量(MW):1512.62

Bleomycin Sulfate is a glycopeptide antibiotic and an anticancer agent for squamous cell carcinomas (SCC) with IC50 of 4 nM in UT-SCC-19A cells.

サイズ 価格(税別)  
JPY 28220.00
JPY 111220.00

質量管理及び製品安全説明書

DNA/RNA Synthesis阻害剤の選択性比較

生物活性

製品説明 Bleomycin Sulfate is a glycopeptide antibiotic and an anticancer agent for squamous cell carcinomas (SCC) with IC50 of 4 nM in UT-SCC-19A cells.
体外試験

UT-SCC-12A and UT-SCC-12B are both more resistant to Bleomycin sulfate with IC50 of 14.2 nM and 13 nM, respectively. [1] Alveolar macrophages incubated with 0.01 μg/mL to 1μg /mL Bleomycin sulfate for 18 hours secretes significantly more fibroblast growth factor than macrophages incubated without Bleomycin sulfate. Macrophages stimulated with Bleomycin sulfate continues to produce significant amounts of fibroblast growth factor even after Bleomycin sulfate is removed and replaced with fresh (Bleomycin sulfate-free) media. Fibroblast growth factor secretion by Bleomycin sulfate-stimulated alveolar macrophages is inhibited by cycloheximide, and the 5-lipoxygenase inhibitors NDGA (nordihydroguaiaretic acid) and BW755c, indicating not only a requirement for protein synthesis but also for metabolites of the 5-lipoxygenase pathway of arachidonic acid metabolism for full expression of activity. [2] Bleomycin sulfate (400 µg/mL) incubation for 24 hours decreases the viability of NTera-2 cells, and increases caspase-3, -8 and -9 activities, Bax and cytoplasmic cytochrome c levels and decreases Bcl-2 levels. [3] In terms of unstable aberrations, the clastogenic effect of Bleomycin sulfate on ADIPO-P2 cells persists for at least 10 days after exposure. Bleomycin sulfate-induced telomere instability in mammalian cells persists for several generations after exposure. Moreover, the appearance of telomere fusions in Bleomycin sulfate-exposed cells 10 days after treatment suggests that Bleomycin sulfate can induce delayed telomere instability. [4]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
F98 M4XkUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX61UYdSOOLCk{GwNFAh|ryv MoHMNlQhcMLi MkLPbY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> M3X1fFI3ODh6N{Gx
POLK WT NEiwcnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfKboFwUUN3ME2xNU446oDLwsJihKkyNjgEoN88US=> NIPQOmEzPjB|MUSwNC=>
POLK KO M{LNfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXxWYZ6UUN3ME20MlA{6oDLwsJihKkyNjl{wrFOwG0> MWqyOlA{OTRyMB?=
POLK CD MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrxVI9KSzVyPUWuOVnjiIoEsfMAjVEvODEEoN88US=> NHzEeXUzPjB|MUSwNC=>
RLE/Abca3 MYfGeY5kfGmxbjDBd5NigQ>? NYLVVVJbOC52wrFOwG0> MlzkNVQ1yqCq NYezdnI2cW6mdXPld{BiKG2xcoDoc4xw\2mlYXygZ4hidmenIH\yc40h\XCrdHjlcIlidC2uaXvlJI1wenCqb3zv[5khfG9iYTD3bYRmNCC|cILlZYQud3W2IH3vdpBpd2yxZ4pCpC=> Ml3qNlU4PjB3M{i=
PMCs M1u0TmZ2dmO2aX;uJGF{e2G7 M3LkSVAvOeLCk{NCpO69\y:vbB?= NXrDO|VCOjUEoHi= M4H2dYNifXOnczDhJIRwe2VvZHXw[Y5l\W62IHnuZ5Jm[XOnIHnuJJRp\SCycn;0[YlvKGyndnXsJI9nKGOxbHzh[4VvNUoEoB?= M3HQb|I2PTl3NkSy
PMCs MlWzSpVv[3Srb36gRZN{[Xl? M2PYS|AvOsLizsznM41t M4POOVI16oDVN{NCpIg> MULpcoR2[2W|IHnuZ5Jm[XOnczDpckB3cW2nboTpckBidmRizsGtV21CKHC{b4TlbY4> NVjRRWdWOjV3OUW2OFI>
PMCs NFrK[lFHfW6ldHnvckBCe3OjeR?= M3vuO|AvOsLizsznM41t NWTESmh5PzJiaB?= MnvPbY5lfWOnczDk[YNz\WG|ZYOgbY4h[3m2b3vldoF1cW5vODDhcoQhTS2lYXTo[ZJqdiCycn;0[Ylv NIW0TGIzPTV7NU[0Ni=>
PMCs Mlf4SpVv[3Srb36gRZN{[Xl? MV:wMlLDqM7:Zz;tcC=> MVWxNk8zPC92ODDo NUHtd5VScW6lcnXhd4V{KGOnbHygcYloemG2aX;u NGLhPHAzPTV7NU[0Ni=>
IMR-32 M2nBT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV63MlXjkJJzMkCgxtVoN22u MXixNwKJmjR6IHi= NX7wZYVVUUN3ME22NEDDvWdxbXygZZQhfGinIHXu[EBw\iB{NDDodpMhd2ZiaX7jeYJifGmxbh?= NX7reWFZOjV3M{[zOFU>
HT1080 NX:5coR6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDy[HUyKM7:TR?= NFLKbnkzPCCqwrC= NHLqWY1t\WGmczD0c{BiKEd{L12g[IVt[Xl? NUHFXXp6OjV3MUi5OlE>
HT1080 NXrZTXM3TnWwY4Tpc44hSXO|YYm= NX65bJN4OSEQvF2= M1LLZVI1KGkEoB?= MW\pcoR2[2W|IHGgdI91\W62IHfsc4JidCCGTlGg[IFu[WenIILld5BwdnOn MWqyOVUyQDl4MR?=
HDFn NGDzT|dEgXSxdH;4bYNqfHliQYPzZZk> M2qySVczKGh? MULJR|UxRTlwM{GlxsA> NF\zWZEzPTJ5Nke5Ni=>
THP-1 NIjwR45EgXSxdH;4bYNqfHliQYPzZZk> M4\xUFczKGh? MoD2TWM2OD12Lke3KS=> MmPSNlUzPzZ5OUK=
HT-29 MoXxR5l1d3SxeHnjbZR6KEG|c3H5 NGrl[lc4OiCq MknVTWM2OD1zMT60PUU> MXGyOVI4Pjd7Mh?=
HCT116  M2TQ[WN6fG:2b4jpZ4l1gSCDc4PhfS=> NUXvNopTPzJiaB?= M3\PZmlEPTB;MUGuN|Qm MmXkNlUzPzZ5OUK=
A431 MmTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13oWFUxNTJyMDDJWS=> NVzWUlFKPDkkgJno M4q4dIlvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> NEDpSFYzPTFyMUK5PS=>
T24 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEL4S|c2OC1{MECgTXU> NUTkdmduPDkkgJno NVW3UVFucW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>? MlOzNlUyODF{OUm=
AY-27  NX6xcGhyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1HVVFUxNTJyMDDJWS=> M33tSFQ56oDLaB?= MUfpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 NE\NXFYzPTFyMUK5PS=>
A549 NI\QXmVHfW6ldHnvckBCe3OjeR?= NYTlPVBNOSEEtXevcWzDqA>? Mn;yNE01QCCq M3vlN4lv[3KnYYPld{B1cGViZYjwdoV{e2mxbjDv[uKhV1CQwrDtVm5C NFrCT2wzPDl4M{[zOS=>
MLE12 MlvxSpVv[3Srb36gRZN{[Xl? NHnDfYMyKML3Zz;tUOKh M2LxeVAuPDhiaB?= MlXobY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mxsBQWE8EoH3SUmE> NGnz[40zPDl4M{[zOS=>
Jurkat NGrUVVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{T4XlIx6oDLzszt NFW2Wm0zPOLCiXlCpC=> MnfXZZJz\XO2czD0bIUh[2WubDDjfYNt\SCjdDD0bIUhTzJicHjhd4U> M2jKdlI1QTF4OEmz
HeLa  Ml;rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPQTnRrUUN3ME2xNE4zyqEQvF2= NGrXeVAzPDd|MkO5Oy=>
C18-4 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYCzZlRiOC1zMECg{txO M3K1NYlvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> M{TMSVI1PTdzOUiy
BMG-1  Moq2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\FeVQxNzhywrFOwIcwdQ>? NEO3dGo{yqCq NEP1TVJqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 NFi4NJAzOzlyNkeyOi=>
A459 NEG3RXhCeG:ydH;zbZMhSXO|YYm= MoLJNVAhdVV? NX:wSIJlPDhiaB?= NW[5V4F{cW6mdXPld{BieG:ydH;zbZM> MVeyN|kxOjd4Nh?=
MOCK MnLKRZBweHSxc3nzJGF{e2G7 MV:xNEBuXQ>? M1rOUFQ5KGh? MYnpcoR2[2W|IHHwc5B1d3Orcx?= M3r2NVI{QTB{N{[2
MMP1 MoLJRZBweHSxc3nzJGF{e2G7 NUTITYpROTBibWW= Mmj0OFghcA>? Ml76bY5lfWOnczDhdI9xfG:|aYO= M3LObFI{QTB{N{[2
A549 NXzYNGhjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjEb5EzODBizszN MV2yOEBpyqB? NYnlTXJS\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JJNq\26rZnnjZY51dHl? MWOyN|gxPTd7Mx?=
HCT-116 M1;PNGFxd3C2b4Ppd{BCe3OjeR?= MUCzM|cvPS9zNTFOwIcwdWx? M32yVFQ5KGh? M3HjRZJm\HWlZYOgeIhmKGyndnXsJI9nKEKOSDDheEBpcWeqIHPvcoNmdnS{YYTpc44> M4DrclI{PzB6Nk[4
HeLa NGrTbpNCeG:ydH;zbZMhSXO|YYm= MmmwN{84NjVxMUWg{txoN22u MlP4OFghcA>? MmrDdoVlfWOnczD0bIUhdGW4ZXygc4YhSkyKIHH0JIhq\2hiY3;uZ4VvfHKjdHnvci=> NFfMdWwzOzdyOE[2PC=>
HCT116 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml:1NE0yODBizsznM41t MYG0PEBp NEnscpdqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 NV3qbIF1OjN3MUiyNFE>
NCM460 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjPNE0yODBizsznM41t NFHoSo81QCCq MYjpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 NGTqfoYzOzVzOEKwNS=>
NT2  NFja[ZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDGVplOOjRiaNMg NI[4NlFNTDVyPUSwNQKBkcL3Zz;tcC=> NXvKVox7OjN|OE[0NlA>
NT2  NYHw[HZyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWW0PEBp M2HoS2xFPTB;MUCwJOK2\y:vbB?= NEPYfXIzOzN6NkSyNC=>
NT2  NF;3fJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorDO|IhcA>? MU\MSFUxRTJy4pEJxtVoN22u M3rJSFI{Ozh4NEKw
NT2  MYDBdI9xfG:|aYOgRZN{[Xl? NET2eYo1ODEkgJpCuYcwdWx? MlLmNlQhcMLi MnjjbY5lfWOnczDzbYdvcW[rY3HueEBqdmO{ZXHz[ZMhcW5iY3HzdIF{\S1|LEisPUBi[3Srdnn0feKh NIP3eJkzOzN6NkSyNC=>
NTera-2 MVzGeY5kfGmxbjDBd5NigQ>? NF7IcIUyOjBizsznM41t NULKUYwzPzJiaB?= M4XyV5Nq\26rZnnjZY51dHliaX7jdoVie2W|IEitbZNweHKxc4ThcoUhdGW4ZXzz MWCyNlgzPTN3NR?=
NCCIT MlGwSpVv[3Srb36gRZN{[Xl? M2\2XVEzOCEQvHevcYw> NYPFO3pJPzJiaB?= NVXOUG1Fe2mpbnnmbYNidnSueTDpcoNz\WG|ZYOgPE1qe2:ycn;zeIFv\SCuZY\lcJM> M2TwVFIzQDJ3M{W1
NTera-2 NWHPZnFWTnWwY4Tpc44hSXO|YYm= MlvpNVIxKM7:Zz;tcC=> MmHWO|IhcA>? NW\xUnhqe2mpbnnmbYNidnSueTDpcoNz\WG|ZYOgWGJCWlNibHX2[Yx{ MofQNlI5OjV|NUW=
NCCIT MYjGeY5kfGmxbjDBd5NigQ>? NVjJbWNbOTJyIN88[{9udA>? M1;Gd|czKGh? NH\nO2N{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnczDURmFTWyCuZY\lcJM> NYjYeGdGOjJ6MkWzOVU>
NCCIT M1rYPGZ2dmO2aX;uJGF{e2G7 M{i0[VEzOCEQvHevcYw> NVfhUm9rPzJiaB?= NHH4eHN{cWewaX\pZ4FvfGy7IHTlZ5Jm[XOnczDHV2ghdGW4ZXzz MoG1NlI5OjV|NUW=
NTera-2 M3;LOmZ2dmO2aX;uJGF{e2G7 NHXFRoEyOjBizsznM41t MVy3NkBp NFK1Z3p{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnczDQdo91\WmwIHPhdoJwdnmuIHzleoVtew>? MkjiNlI5OjV|NUW=
NCCIT NFnRfpRHfW6ldHnvckBCe3OjeR?= M3rJUFEzOCEQvHevcYw> MlL1O|IhcA>? NEHwXlF{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnczDQdo91\WmwIHPhdoJwdnmuIHzleoVtew>? NYnoR3NDOjJ6MkWzOVU>
NTera-2 NWG2UI03TnWwY4Tpc44hSXO|YYm= NGnz[2MyOjBizsznM41t MWS3NkBp MY\zbYdvcW[rY3HueIx6KGmwY4LlZZNmeyCOUF:gcIV3\Wy| M1PpNlIzQDJ3M{W1
NCCIT NIm5UmxHfW6ldHnvckBCe3OjeR?= M1m3PVEzOCEQvHevcYw> NW[0ZWRFPzJiaB?= NHP0bYV{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnczDMVG8hdGW4ZXzz NHvLcXIzOjh{NUO1OS=>
MDA-MB-468 MkjnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnrUNQKBmzJyMNMg{txoN22O M33p[FI1KGh? MULpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 NVXuV5BCOjJ6MUmxPVY>
231-H2N M4XkeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXWw5qCUOjBywrFOwIcwdUx? MUWyOEBp M{jKXYlvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> M3Ps[|IzQDF7MUm2
A549  NYfOemx7TnWwY4Tpc44hSXO|YYm= M2fUTFIxOC92MECg{txO NG\ScoRz\XO3bITzJIlvKGFiZH;z[U1z\XOyb37zbZZmKGmwY4LlZZNmKGmwIGLPVy=> M{izeFIzPzd|Nkm3
A549  M4LzcWZ2dmO2aX;uJGF{e2G7 M2C1SVAuPDByIN88US=> MoCzNk01QCCq MnPzZ4F2e2W|IH3vdoUhdXSGTlGgeIhidiCwRF7BJIRidWGpZR?= M2POWFIzPzd|Nkm3
A549  NEHaRXpHfW6ldHnvckBCe3OjeR?= MoTaNVAxKM7:TdMg MWCw5qCUPDhiaB?= NXfienQy[2G3c3XzJINie3Cjc3WtN{Bi[3SrdnH0bY9v M2P4e|IzPzd|Nkm3
A549  NGfPbYRHfW6ldHnvckBCe3OjeR?= MXixNFAh|ryPwrC= M{i4NFDjiJN2ODDo MWfjZZV{\XNiUFvENUBkdGWjdnHn[S=> MYWyNlc4OzZ7Nx?=
A549  MUXGeY5kfGmxbjDBd5NigQ>? Ml;3NVAxKM7:TdMg M2XhXVDjiJN2ODDo M3LBUoNifXOnczDtbZRw[2ixbnTybYFtKGyxY3HsbZpifGmxbjDv[kBD[Xh? MXqyNlc4OzZ7Nx?=
A549  MWfGeY5kfGmxbjDBd5NigQ>? MnS3NVAxKM7:TdMg MknhNQKBmzR6IHi= M2r2NYRm[3KnYYPld{BOVVBiYX7kJGFVWCCuZY\lcJM> NFHiVogzOjd5M{[5Oy=>
MCF-7/Her-18  MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVewMlQzNTF5MECg{txoN22O NVexWlVNOjRiaB?= M2nnfolvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> NUjxRmNUOjJ4MkG0NFQ>
MCF-7 NIXSZ2dRTFRxUFPJJHRz\WG2bXXueC=> MoHHNE4zPSEQvHevcYwv NU[3bIVmOS12IHi= NH3GRXh{cG:5czDzbYdvcW[rY3HueEApWMLiPDCwMlA2MSCleYTveI95cWNiZX\m[YN1 Mn3HNlI2QTF{OES=
MDA-MB-231 NEG5d5NRTFRxUFPJJHRz\WG2bXXueC=> MmmyNE4zPSEQvHevcYwv NV3WV2RKOS12IHi= MkT1d4hwf3Nic3nncolncWOjboSgLHDDqDxiMD6wOUkh[3m2b4TvfIlkKGWoZnXjeC=> MkPtNlI2QTF{OES=
MDA-MB-235  MWjQSHQwWEOLIGTy[YF1dWWwdB?= NH30TIExNjJ3IN88[{9udC5? MY[xMVQhcA>? M4HKUZNpd3e|IIPp[45q\mmlYX70JEhRyqB:IECuNFUqKGO7dH;0c5hq[yCnZn\lZ5Q> NEntfGYzOjV7MUK4OC=>
MCF-7 NFW5OW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoXNNE0zKM7:Zz;tcE4> MVWyOE81QCCq NIO4WW5GSzVyPUGuNkDPxGdxbVy= M{DZTVIzPTlzMki0
NCCIT  MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rscFIx6oDVMUSwxsDPxGdxbXy= Mnv2O|IhcA>? NGrtbVVNTDVyPUGyNOKh|rypL33sxsA> MkXuNlI2PjJzNkC=
NCCIT  M{HzT2Z2dmO2aX;uJGF{e2G7 NEPHW4g4OiCq NX:5c2pPe2mpbnnmbYNidnSueTDpcoNz\WG|ZYOgZ4F{eGG|ZT2zJIFkfGm4aYT5xsA> MW[yNlU3OjF4MB?=
NCCIT  NV:0emMzTnWwY4Tpc44hSXO|YYm= MYi3NkBp NGfIcpp{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnczDjZZNx[XOnLUigZYN1cX[rdIpCpC=> M4jB[VIzPTZ{MU[w
NCCIT  MorOSpVv[3Srb36gRZN{[Xl? NUPz[G4yPzJiaB?= NX;BXI9Oe2mpbnnmbYNidnSueTDpcoNz\WG|ZYOgZ4F{eGG|ZT25JIFkfGm4aYT5xsA> M4fBSVIzPTZ{MU[w
NCCIT  NVzkSG1PTnWwY4Tpc44hSXO|YYm= NXXofZFCPzJiaB?= M3Poc5Nq\26rZnnjZY51dHliaX7jdoVie2W|IFLBXEBt\X[nbB?= NVfqZZJEOjJ3NkKxOlA>
NCCIT  NFfOTnBHfW6ldHnvckBCe3OjeR?= NXroZYZzPzJiaB?= MmHJd4lodmmoaXPhcpRtgSCmZXPy[YF{\XNidHjlJGJkdC1{IHPvcpRmdnR? Ml;DNlI2PjJzNkC=
NCCIT  NHPpWIVHfW6ldHnvckBCe3OjeR?= M1;6RlczKGh? M1i2V5Nq\26rZnnjZY51dHliZHXjdoVie2W|IITo[UBEgXRvYzDs[ZZmdA>? MYWyNlU3OjF4MB?=
HeLa NHLiOlJHfW6ldHnvckBCe3OjeR?= MYmzNE84OCEQvHevcYw> MoPONlTDqGh? MXvpcoNz\WG|ZYOgeIhmKG2UTlGgcIV3\Wy|IH;mxsBxPTQxvJzBWG0teDJzwrDhcoTDqEeDRFS0OS=> MViyNlQ5Pzl|Nx?=
MCF-7  NHu3eHNHfW6ldHnvckBCe3OjeR?= NXvpTFNXOzBxN{Cg{txoN22u MkXpNlTDqGh? M1\ieIlv[3KnYYPld{B1cGVibWLORUBt\X[nbIOgc4bDqHB3M,-8kGFVVSyyMkJCpIFv\MLiR1HESFQ2 MneyNlI1QDd7M{e=
HeLa NHPVT2lEgXSxdH;4bYNqfHliQYPzZZk> MoP6N|AwPzBizsznM41t NXzIRWJ7OjUEoHi= NVHD[41wcW6mdXPld{BpcWeqbImgd4lodmmoaXPhcpQhdGW4ZXzzJI9nKG[{YXft[Y51\WRiRF7BJJJmdGWjc3WgbY51dyC2aHWgZ5l1d3CuYYPt NXvmdVJlOjJ2OEe5N|c>
MCF-7  NED0fZJEgXSxdH;4bYNqfHliQYPzZZk> NF\jNWU{OC95MDFOwIcwdWx? NXPZe25ZOjUEoHi= NFTScZhqdmS3Y3XzJIhq\2iueTDzbYdvcW[rY3HueEBt\X[nbIOgc4Yh\nKjZ33lcpRm\CCGTlGgdoVt\WG|ZTDpcpRwKHSqZTDjfZRweGyjc32= NWjrbXcyOjJ2OEe5N|c>
NT2 NHPu[4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjmVVkyODBvNkCwxsDPxGdxbXy= NI\QbpEzPCCq NF3FZ|VKSzVyPUSwNEDDvWdxbXy= NILKN48zOjR4OUm1Ni=>
NT2 NV70eI4yTnWwY4Tpc44hSXO|YYm= MVe0NFDDqM7:Zz;tcC=> MWiyOEBp M1u5WpNq\26rZnnjZY51dHliaX7jdoVie2W|IHPhd5Bie2VvMzy4MFkh[WO2aY\peJnDqA>? MV2yNlQ3QTl3Mh?=
NT2 M2nnTWZ2dmO2aX;uJGF{e2G7 MmTnOFAxyqEQvHevcYw> NYeyW3VVOjRiaB?= NHvINIR{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnczDCRXghdGW4ZXy= NGLhUpkzOjR4OUm1Ni=>
NT2 NITCO4ZHfW6ldHnvckBCe3OjeR?= NVrUWG9zPDBywrFOwIcwdWx? NHq1VYEzPCCq Mknxd4lodmmoaXPhcpRtgSCmZXPy[YF{\XNiQnPsMVIhdGW4ZXy= MWiyNlQ3QTl3Mh?=
CHO M2qzNWZ2dmO2aX;uJGF{e2G7 M4HJVlIvPcLizsznM41t NXXhfYFoOThiaD:2JIQ> M2nK[Ylv\HWlZYRCpJBmenOrc4TlcoNmKG:oIHPodo9ud3OxbXWg[IFu[Wen MYCyNlI{ODF7NR?=
Jurkat MkjGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnX3NE0yODEEoN88[{9udA>? NET0fJEzPCCq NEmxNWpienKnc4TzJJRp\SClZXzsJIN6[2ynIHH0JJRp\SCJMjDwbIF{\Q>? NHrY[|YzOjJ{M{OzNi=>
Jurkat MmPNSpVv[3Srb36gRZN{[Xl? MVuzNOKh|rypL33s MlPlNlQhcA>? MX;pcoNz\WG|ZYOgeIhmKHC{b4TlbY4hdGW4ZXzzJI9nKGO7Y3zpcpMhTDNuIFGgZY5lKEJz MkLlNlIzOjN|M{K=
Jurkat NEjJcGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1j6T|AuOTBywrFOwIcwdWx? MWGyOEBp NGXjU|dqdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44hcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZIhf2m2aDDhckBKSzVyII\hcJVmKG:oIEGwNO69\y:vTB?= NGrCVZYzOjJ{M{OzNi=>
Jurkat MlG4SpVv[3Srb36gRZN{[Xl? NVjoR4I1OzEEoN88[{9udA>? MljjNlQhcA>? MlrXbY5kemWjc3XzJJRp\SCnZn\lZ5Qhd2ZicInjcollcW:wZTDvckBxcG:|cHjvdplt[XSrb36gcIV3\Wy|IH;mJIhqe3SxbnWgTFJCNlh? NILFbIEzOjJ{M{OzNi=>
U2OS EGFPnls NFnpZVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXBXGgxNTMEoN88[{9udA>? MUmyOEBp MU\pcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 MoX3NlE5OTFyMEe=
U2OS KuEnls NWSxUJA4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXNNE0zyqEQvHevcYw> MnfzNlQhcA>? MmXsbY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> NVX4XXoyOjF6MUGwNFc>
MCF-7 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rrUFAuPDByIN88US=> NFfrcWg4OiCq MXLMR|UxRTF3MT64xsDPxE1? NHLaOGszOTdyM{K5NS=>
MCF-7/Adr  MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVmwMVQxOCEQvF2= MVy3NkBp NX\H[GxyVEN3ME21PE42yqEQvF5CpC=> NGnDTnQzOTdyM{K5NS=>
WI-38 NX\Id4ZYTnWwY4Tpc44hSXO|YYm= MmDXNE81OC96MPMAje69\y:vbNMg M3rPWFMhcA>? MYPpcoR2[2W|IHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRiaX7jdoVie2ViaX6geIhmKE2QIH\y[ZF2\W6ledMg M4jaXVIyPTl7NkGy
hBMSC M2q0U2Z2dmO2aX;uJGF{e2G7 M3PQXVAwPDBxOEFihKnPxGdxbX|CpC=> NFSxU5o{KGh? NXn1RW5QcW6mdXPld{BiKGOxbnPlcpRz[XSrb36t[IVx\W6mZX70JIlv[3KnYYPlJIlvKHSqZTDNUkBnemWzdXXuZ5nDqA>? MoTLNlE2QTl4MUK=
NCI-H23 M375UGZ2dmO2aX;uJGF{e2G7 MlXuNE81OC96MPMAje69\y:vbNMg NEW5VZk{KGh? NH7GdoNqdmS3Y3XzJIEh[2:wY3XueJJifGmxbj3k[ZBmdmSnboSgbY5kemWjc3WgbY4hfGinIF3OJIZz\XG3ZX7jfeKh M1izV|IyPTl7NkGy
A-549 NVn1bWZITnWwY4Tpc44hSXO|YYm= M4PaUlAwPDBxOEFihKnPxGdxbX|CpC=> M4HkSFMhcA>? MV;pcoR2[2W|IHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRiaX7jdoVie2ViaX6geIhmKE2QIH\y[ZF2\W6ledMg Mkn5NlE2QTl4MUK=
PBL  MWPGeY5kfGmxbjDBd5NigQ>? NHHzRZExNzRyL{iw5qCK|rypL33sxsA> NWfLbotMOyCq MUXpcoR2[2W|IHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRiaX7jdoVie2ViaX6geIhmKE2QIH\y[ZF2\W6ledMg MX2yNVU6QTZzMh?=
pol β −/− M{jlWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2nVS|AvOjVvMkCwxsDPxGdxbXy= M4jXTlI1yqCq Mlft[IVkemWjc3XzJINmdGxidnnhZoltcXS7IIfpeIghcW6lcnXhd4lv\yClb37j[Y51emG2aX;ud:Kh Ml3PNlEzPTF7NES=
pol β +/+ MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\BXYc3OC5{NT2yNFDDqM7:Zz;tcC=> Mnz4NlTDqGh? MW\k[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHlid3n0bEBqdmO{ZXHzbY5oKGOxbnPlcpRz[XSrb37zxsA> NF\iNWszOTJ3MUm0OC=>
pol β −/− MXvGeY5kfGmxbjDBd5NigQ>? MWOwMVIvPSEQvHevcYw> NWXDZVNiOiCq M3PMOYNifXOnczDEUmEh\GGvYXfl NXvPenpkOjF{NUG5OFQ>
pol β +/+ NGHBbWVHfW6ldHnvckBCe3OjeR?= MWKwMVIvPSEQvHevcYw> MojzNkBp MXfjZZV{\XNiRF7BJIRidWGpZR?= NHuyWHkzOTJ3MUm0OC=>
pol β −/− MkfPSpVv[3Srb36gRZN{[Xl? Mn3QNE02KM7:Zz;tcC=> NUG5W5BnPDhiaB?= MXHjZZV{\XNibXnjdo9vfWOuZYXzJIRwe2ViYX7kJJRqdWViZHXw[Y5l\W62bIm= MVeyNVI2OTl2NB?=
pol β +/+ NX\ON4NtTnWwY4Tpc44hSXO|YYm= NHKwV40xNTVizsznM41t NVLpXoZiPDhiaB?= NH;wV3lk[XW|ZYOgcYlkem:wdXPs[ZV{KGSxc3WgZY5lKHSrbXWg[IVx\W6mZX70cJk> NX7ZS4F7OjF{NUG5OFQ>
TK6  MkHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkK1NlUuOTVyIN88[{9udA>? M3S2UFk3KGh? NEPqS29qdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 NUDObJJZOjFyOEG0PFc>
TK6  sLUC+Apn1 M4PISmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1T6clI2NTF3MDFOwIcwdWx? NU\IXVVjQTZiaB?= MoTrbY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> MkmzNlExQDF2OEe=
TK6 sAPE1+Apn1 NWjRdVR3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXyyOU0yPTBizsznM41t MUG5OkBp Mlnvd4lodmmoaXPhcpRtgSCrbnjpZol1eyClZXzsJIdzd3e2aDDkc5NmKGSncHXu[IVvfGy7 NXPs[pA2OjFyOEG0PFc>
HCT116 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPSNlUuOTVyIN88[{9udA>? NGHrVY86PiCq MlXBbY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> NE\lNJczOTB6MUS4Oy=>
HCT116 sLUC+Apn1 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX:yOU0yPTBizsznM41t NGHEWlM6PiCq NYPyPIVFcW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>? M{OxUVIyODhzNEi3
HCT116 sAPE1+Apn1 MlzmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFrHZpEzPS1zNUCg{txoN22u M1zTXFk3KGh? MnnEd4lodmmoaXPhcpRtgSCrbnjpZol1eyClZXzsJIdzd3e2aDDkc5NmKGSncHXu[IVvfGy7 M2DNT|IyODhzNEi3

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

体内試験 Day 7 post-Bleomycin sulfate, CD45+ cells in BALf in NOX-/- is 1.7-fold > WT, 57% of which are Mf that decreases by 67% in WT and 83% in NOX-/- by Day 21. [5]

お薦めの試験操作(参考用のみ)

細胞試験:

[4]

+ 展開
  • 細胞株: ADIPO-P2 cells
  • 濃度: 2.5 μg/mL
  • 反応時間: 30 minutes
  • 実験の流れ:

    ADIPO-P2 cells are grown in D-MEM high glucose medium supplemented with 20% fetal calf serum, penicillin (100 U/mL) and streptomycin (100 μg/mL) at 37 °C and 5% CO2 atmosphere. Cells are cultured as monolayer in TC25 Corning flasks containing 1.5 × 105 cells/mL. For each experiment, two flasks are set up, one for the control and one for the treated culture. During the log phase of growth ADIPO-P2 cells are treated with a 30 minutes pulse of 2.5 μg/mL of Bleomycin sulfate. Control cultures are set up in parallel but not exposed to Bleomycin sulfate. Time of exposure and concentration of Bleomycin sulfate are chosen according to previous studies carried out in our laboratory with mammalian cells exposed to Bleomycin sulfate. At the end of the pulse treatment with Bleomycin sulfate, the cells are washed twice with Hank's balanced salt solution and kept in culture with fresh culture medium until harvesting. Cells are continuously maintained in culture during 5 passages or subcultures after treatment. Subcultivation is carried out whenever the cultures became confluent (approximately 4 × 105 cells/mL of culture medium). To estimate cell growth, at the time of subcultivation cells are collected by trypsinization, an aliquot of about 200 μL stained with 0.4% trypan blue, and the number of viable cells is determined. Cells are then suspended in fresh culture medium and dispensed into new culture flasks containing 1 × 105 cells/mL to continue growing. The rest of the cells is discarded or dispensed in another flask for cytogenetic analysis, which is performed at 18 hours and 10 days after the end of treatments. To analyze chromosomal aberrations, colchicine (0.1 μg/mL) is added to cell cultures during the last 3 hours of culture. Chromosome preparations are made following standard procedures. After harvesting, cells are hypotonically shocked, fixed in methanol:acetic acid (3:1), spread onto glass slides and processed for PNA-FISH. Two independent experiments are carried out.


    (参考用のみ)
動物試験:

[7]

+ 展開
  • 動物モデル: CD-1 mice
  • 製剤: Saline
  • 投薬量: 5 mg/kg, 2 ml/kg
  • 投与方法: Administered via i.t.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 100 mg/mL (66.11 mM) warming
Water 100 mg/mL (66.11 mM)
Ethanol Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
Saline
混合させたのち直ちに使用することを推奨します。
30 mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 1512.62
化学式

C55H85N17O25S4

CAS No. 9041-93-4
保管
in solvent
別名 NSC125066

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (g) = 濃度 (mol/L) x 体積 (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03596918 Recruiting AIDS-Related Kaposi Sarcoma|Human Immunodeficiency Virus 1 Positive AIDS Malignancy Consortium|National Cancer Institute (NCI)|The EMMES Corporation|University of Arkansas|University of California Los Angeles October 10 2018 Phase 1
NCT03596918 Recruiting AIDS-Related Kaposi Sarcoma|Human Immunodeficiency Virus 1 Positive AIDS Malignancy Consortium|National Cancer Institute (NCI)|The EMMES Corporation|University of Arkansas|University of California Los Angeles October 10 2018 Phase 1
NCT03067181 Recruiting Adult Germ Cell Tumor|Childhood Extracranial Germ Cell Tumor|Childhood Germ Cell Tumor|Extragonadal Embryonal Carcinoma|Grade 2 Immature Ovarian Teratoma|Grade 3 Immature Ovarian Teratoma|Malignant Germ Cell Tumor|Stage I Ovarian Choriocarcinoma|Stage I Ovarian Embryonal Carcinoma|Stage I Ovarian Teratoma|Stage I Ovarian Yolk Sac Tumor|Stage I Testicular Choriocarcinoma AJCC v6 and v7|Stage I Testicular Embryonal Carcinoma AJCC v6 and v7|Stage I Testicular Yolk Sac Tumor AJCC v6 and v7|Stage II Ovarian Choriocarcinoma|Stage II Ovarian Embryonal Carcinoma|Stage II Ovarian Yolk Sac Tumor|Stage II Testicular Choriocarcinoma AJCC v6 and v7|Stage II Testicular Embryonal Carcinoma AJCC v6 and v7|Stage II Testicular Yolk Sac Tumor AJCC v6 and v7|Stage III Ovarian Choriocarcinoma|Stage III Ovarian Embryonal Carcinoma|Stage III Ovarian Yolk Sac Tumor|Stage III Testicular Choriocarcinoma AJCC v6 and v7|Stage III Testicular Embryonal Carcinoma AJCC v6 and v7|Stage III Testicular Yolk Sac Tumor AJCC v6 and v7|Stage IV Ovarian Choriocarcinoma|Stage IV Ovarian Embryonal Carcinoma|Stage IV Ovarian Yolk Sac Tumor|Testicular Mixed Choriocarcinoma and Embryonal Carcinoma|Testicular Mixed Choriocarcinoma and Teratoma|Testicular Mixed Choriocarcinoma and Yolk Sac Tumor Children''s Oncology Group|National Cancer Institute (NCI) May 8 2017 Phase 3
NCT03067181 Recruiting Adult Germ Cell Tumor|Childhood Extracranial Germ Cell Tumor|Childhood Germ Cell Tumor|Extragonadal Embryonal Carcinoma|Grade 2 Immature Ovarian Teratoma|Grade 3 Immature Ovarian Teratoma|Malignant Germ Cell Tumor|Stage I Ovarian Choriocarcinoma|Stage I Ovarian Embryonal Carcinoma|Stage I Ovarian Teratoma|Stage I Ovarian Yolk Sac Tumor|Stage I Testicular Choriocarcinoma AJCC v6 and v7|Stage I Testicular Embryonal Carcinoma AJCC v6 and v7|Stage I Testicular Yolk Sac Tumor AJCC v6 and v7|Stage II Ovarian Choriocarcinoma|Stage II Ovarian Embryonal Carcinoma|Stage II Ovarian Yolk Sac Tumor|Stage II Testicular Choriocarcinoma AJCC v6 and v7|Stage II Testicular Embryonal Carcinoma AJCC v6 and v7|Stage II Testicular Yolk Sac Tumor AJCC v6 and v7|Stage III Ovarian Choriocarcinoma|Stage III Ovarian Embryonal Carcinoma|Stage III Ovarian Yolk Sac Tumor|Stage III Testicular Choriocarcinoma AJCC v6 and v7|Stage III Testicular Embryonal Carcinoma AJCC v6 and v7|Stage III Testicular Yolk Sac Tumor AJCC v6 and v7|Stage IV Ovarian Choriocarcinoma|Stage IV Ovarian Embryonal Carcinoma|Stage IV Ovarian Yolk Sac Tumor|Testicular Mixed Choriocarcinoma and Embryonal Carcinoma|Testicular Mixed Choriocarcinoma and Teratoma|Testicular Mixed Choriocarcinoma and Yolk Sac Tumor Children''s Oncology Group|National Cancer Institute (NCI) May 8 2017 Phase 3
NCT02166463 Recruiting Ann Arbor Stage IIB Hodgkin Lymphoma|Ann Arbor Stage IIIB Hodgkin Lymphoma|Ann Arbor Stage IV Hodgkin Lymphoma|Ann Arbor Stage IVA Hodgkin Lymphoma|Ann Arbor Stage IVB Hodgkin Lymphoma|Childhood Hodgkin Lymphoma|Classic Hodgkin Lymphoma National Cancer Institute (NCI) March 16 2015 Phase 3
NCT02166463 Recruiting Ann Arbor Stage IIB Hodgkin Lymphoma|Ann Arbor Stage IIIB Hodgkin Lymphoma|Ann Arbor Stage IV Hodgkin Lymphoma|Ann Arbor Stage IVA Hodgkin Lymphoma|Ann Arbor Stage IVB Hodgkin Lymphoma|Childhood Hodgkin Lymphoma|Classic Hodgkin Lymphoma National Cancer Institute (NCI) March 16 2015 Phase 3

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

よくある質問(FAQ)

  • 質問1:

    what is the ratio between bleomycin A2 and bleomycin B2 in your product?

  • 回答:

    The content of Bleomycin A2 and Bleomycin B2 is 62% and 29% respectively.

DNA/RNA Synthesisシグナル伝達経路

相関DNA/RNA Synthesis製品

Tags: Bleomycin Sulfateを買う | Bleomycin Sulfate ic50 | Bleomycin Sulfate供給者 | Bleomycin Sulfateを購入する | Bleomycin Sulfate費用 | Bleomycin Sulfate生産者 | オーダーBleomycin Sulfate | Bleomycin Sulfate化学構造 | Bleomycin Sulfate分子量 | Bleomycin Sulfate代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID